Drugs / ATG
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06108739 Background | Nov 2023 → Dec 2024 | hematopoietic and lymphoid cell neoplasm | Peking University People's Hospital | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06108739 ↗ |
| Route | Intravenous | “rabbit ATG (Sangstat-Genzyme) 2.5mg/kg/day i.v.” NCT06108739 ↗ |